These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19682080)

  • 1. Combined therapy in the treatment of dyslipidemia.
    Reiner Z
    Fundam Clin Pharmacol; 2010 Feb; 24(1):19-28. PubMed ID: 19682080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
    Farnier M
    Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What combination therapy with a statin, if any, would you recommend?
    Dujovne CA; Williams CD; Ito MK
    Curr Atheroscler Rep; 2011 Feb; 13(1):12-22. PubMed ID: 21107758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
    Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
    Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
    Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
    Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates in combination with statins in the management of dyslipidemia.
    Jacobson TA; Zimmerman FH
    J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.
    Insull W
    South Med J; 2006 Mar; 99(3):257-73. PubMed ID: 16553100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG
    Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.